{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(7)"],"submitter":["Colhoun HM"],"funding":["Novo Nordisk A/S"],"pubmed_abstract":["The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min<sup>-1</sup> 1.73 m<sup>-</sup><sup>2</sup>, persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence i"],"journal":["Nature medicine"],"pagination":["2058-2066"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11271413"],"repository":["biostudies-literature"],"pubmed_title":["Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial."],"pmcid":["PMC11271413"],"pubmed_authors":["Plutzky J","Deanfield J","Lingvay I","Node K","Rathor N","Tuttle KR","Lincoff AM","Wilding JPH","Brown-Frandsen K","Kahn SE","Mann JFE","Parkhomenko A","Ryden L","Idorn T","Brown PM","Colhoun HM"],"additional_accession":[]},"is_claimable":false,"name":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.","description":"The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min<sup>-1</sup> 1.73 m<sup>-</sup><sup>2</sup>, persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence i","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-01T06:55:37.2Z","creation":"2025-04-19T13:11:38.367Z"},"accession":"S-EPMC11271413","cross_references":{"pubmed":["38796653"],"doi":["10.1038/s41591-024-03015-5"]}}